

Table 5. Comparison between approved biologics for CRSwNP expressed in mean difference (MD) and 95% CI.

Biologic	Patient-Important Outcomes						Surrogate Outcomes	
	SNOT-22 (0-110)	Symptoms VAS (0-110cm)	Smell UPSIT (0-40)	Rescue OCS	Rescue surgery	Adverse events	Nasal polyp size (0-8)	CT score LMK (0-24)
Dupilumab	-19.91(22.5, -17.32)	-3.25(-4.31, -2.18)	10.96 (9.75, 12.17)	-21.73 (-24.61, -18.22) RR 0.32 (0.23, 0.43)	-16.35 (-18.13, -13.48) RR 0.22 (0.14, 0.36)	0.13 (-8.12, 9.88) RR 1.0 (0.88, 1.13)	-2.04 (-2.73, -1.35)	-7.51 (-10.13, -4.89)
Omalizumab	-16.09(19.88, -12.30)	-2.09 (-3.15, -1.03)	3.75 (2.14, 5.35)	-12.46 (-23.65, -12.78) RR 0.61 (0.26, 1.4)	-7.40 (-11.04, -2.43) RR 0.65 (0.26, 0.66)	-2.60 (-15.58, 13.28) RR 0.96 (0.79, 1.18)	-1.09 (-1.70, -0.49)	-2.66 (-5.70, -0.37)
Mepolizumab	-12.89 (-16.58, -9.19)	-1.82 (-3.13, -0.5)	6.13 (4.07, 8.19)	-10.23 (-15.98, -2.88) RR 0.68 (0.50, 0.91)	-12.33 (-15.56, -7.22) RR 0.41 (0.26, 0.66)	-3.07 (-13.44, 9.07) RR 0.96 (0.82, 1.12)	-1.06 (-1.79, -0.34)	No data

VAS = visual analogic scale; SNOT-22 = 22-item Sino-Nasal Outcome Test; UPSIT = University of Pennsylvania Smell Identification Test; CT = computed tomography; LMK = Lund-McKay; RR = relative risk; OCS = oral corticosteroid